Ceramide was quantified by the diacylglycerol kinase
assay, as described previously.
34 35 In brief, after
incubation with the treatment drug, cells were pelleted by
centrifugation (300
g for 10 minutes), washed twice with
ice-cold PBS, and extracted with 0.6 ml of chloroform:methanol:l N HC1
(100:100:1, v/v/v). Lipids in the organic-phase extract were dried
under N
2 and subjected to mild alkaline
hydrolysis (0.1 N methanolic KOH for 1 hour at 37°C) to remove
glycerophospholipids. Samples were reextracted, and the organic phase
was dried under N
2. Ceramide contained in each
sample was resuspended in a 100-μl reaction mixture containing 150μ
g cardiolipin (Matreya), 280 μM diethylenetriaminepenta-acetic
acid (DTPA), 51 mM octyl-15-
d-glucopyranoside
(Calbiochem-Novabiochem Corp., San Diego, CA), 50 mM NaC1, 51 mM
imidazole, 1 μM EDTA, 12.5 mM MgC1
2, 2 μM
dithiothreitol, 0.7% glycerol, 70 μM β-mercaptoethanol, 1
mM ATP, 10 μCi of [γ-
32P]ATP (3000 Ci/mmol;
Dupont New England Nuclear, Boston, MA), 35 μg/ml
Escherichia
coli diacylglycerol kinase (Calbiochem-Novabiochem Corp.),
pH 6.5. After 60 minutes at room temperature, the reaction was stopped
by extraction of lipids with 1 ml chloroform:methanol:l N HC1
(100:100:1), 170 μl buffered saline solution (135 mM NaC1, 1.5 mM
CaC1
2, 0.5 mM MgC1
2, 5.6 mM
glucose, and 10 mM Hepes, pH 7.2), and 30 μl of 100 mM EDTA. The
lower organic phase was dried under N
2. Ceramide
1-phosphate was resolved by thin-layer chromatography on silica gel 60
plates (MCB Manufacturing Chemicals, Cincinnati, OH) using a solvent
system of chloroform:methanol:acetic acid (65:15:5) and detected by
autoradiography, and incorporated
32P was
quantified by liquid scintillation counting. The level of ceramide was
determined by comparison with a standard curve generated concomitantly
from known amounts of ceramide (ceramide type III; Sigma).
Diacylglycerol was quantified in a similar manner to ceramide, except
the alkaline hydrolysis step was omitted.